Theratechnologies Inc. said the European Commission granted marketing authorization for its HIV drug Trogarzo to treat adult patients with multidrug-resistant infection.
Trogarzo is administered into a vein once every 14 days by a trained medical professional and used in combination with other antiretroviral medications. The drug attaches to the CD4+ protein molecules on host cells and blocks the HIV virus from infecting the cells. Antiretroviral drugs are medications that do not kill or cure the HIV virus but can slow down or prevent its growth.
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended Trogarzo's approval in July.
The U.S. Food and Drug Administration granted approval for Trogarzo in March 2018.
Montreal-based Theratechnologies acquired the commercialization rights to Trogarzo in the U.S., the EU, Canada, Israel, Norway, Russia and Switzerland from TaiMed Biologics Inc.
